Five Things Almost Every Article About Medicare Drug Appeals Gets Wrong

If your Medicare drug plan denies a prescription, the internet will tell you that you have 65 days to appeal, that the plan has 7 days to decide, and that your doctor can handle the whole thing.

All three are wrong, or wrong often enough to hurt you.

I went through the actual regulations — 42 CFR Part 423, subparts M and U — alongside CMS's own guidance and the Federal Register notice that sets this year's dollar thresholds. Here is where the published version diverges from the governing one, and what to do about each.

This matters most for GLP-1 medications right now, because they generate an unusual volume of denials, but the rules below apply to any Part D drug.

1. "You have 65 days to appeal" — a rebuttable presumption dressed up as a deadline

The regulation says you must file within *60 calendar days after receipt* of the denial notice (42 CFR 423.582). Separately, it presumes you received the notice 5 calendar days after its date** — which is where the familiar 65 comes from.

The word doing the work is presumed. The regulation adds: "unless there is evidence to the contrary." If the plan can show you received it earlier, those five days evaporate.

CMS itself is inconsistent about this across its own pages. At Levels 1 and 2 it publishes the 65-day version. At Level 3 it publishes "60 calendar days from the date of the notice" — the stricter reading — for the same underlying rule.

What to do: count 60 days from the date printed on the notice. That satisfies every reading, and it costs you nothing.

2. "Redeterminations take 7 days" — true for one kind of request, not the other

Under 42 CFR 423.590, the deadlines split:

• Standard benefit request (you want the drug covered): 7 calendar days
• Standard payment request (you already paid and want reimbursement): 14 calendar days
• Expedited request: 72 hours

The 14-day payment track is real and is almost universally omitted from consumer explanations. If you paid out of pocket and are seeking reimbursement, you are on a different clock than the one you probably read about — and knowing that stops you from concluding the plan has blown a deadline when it hasn't.

3. "If the plan misses its deadline, refile" — no, it escalates automatically

This is the error with the largest practical cost, because it makes people restart something they had already won.

Under 42 CFR 423.590(c) and (e), if the plan fails to decide within its timeframe, two things happen by operation of the regulation:

1. The failure itself counts as an adverse decision — a denial.
2. The plan must forward your request to the Independent Review Entity within 24 hours.

Your appeal moves to Level 2 on its own. You do not refile, and you have not lost your place. If you restart the process instead, you throw away the escalation you were entitled to and reset your own clock.

If a deadline passes and you hear nothing, the correct move is to ask the plan for confirmation that your case was forwarded to the IRE — not to submit a fresh appeal.

4. "Your doctor can appeal for you at every level" — their standing ends after Level 2

Your prescriber can request a redetermination (Level 1) and an Independent Review Entity reconsideration (Level 2) on your behalf.

At Level 3 (the hearing level, decided by an administrative law judge or an attorney adjudicator — another commonly missed detail, since no hearing is always required), Level 4 (the Medicare Appeals Council), and Level 5 (federal district court), your prescriber cannot act for you unless you formally appoint them as your representative.

What to do: if your appeal looks likely to go past Level 2, sort out representation early rather than discovering the gap at a filing deadline.

5. "There's a minimum dollar amount to appeal" — not until Level 3

There is no amount-in-controversy threshold at Levels 1 or 2. I searched the full text of Subpart M for it: every mention is a forward-reference to the rule governing Level 3 or Level 5, never a condition on the plan's own review or the IRE's.

The first dollar gate appears at Level 3, and it is adjusted annually. For calendar year 2026 it is $200 for a hearing and $1,960 for judicial review — both increased from 2025's $190 and $1,900 (CMS–4209–N, 90 FR 55869, published December 4, 2025).

Two warnings if you go looking for these figures yourself:

• Do not rely on citations to 42 CFR 423.1970. That section is now marked [Reserved] — the provision moved to §423.2006 in a 2017 restructuring. Plenty of otherwise-credible pages still cite the repealed section.
• CMS's own district-court page has been stale. At the time I checked, it still listed the 2025 figure of $1,900. Cite the Federal Register notice, not that page.

The ladder, in plain terms

Level 1 — Redetermination. Your plan reconsiders, using a reviewer who was not involved the first time. File within 60 days of receipt. They decide in 7 days (benefit), 14 days (payment), or 72 hours (expedited).

Level 2 — Reconsideration. An Independent Review Entity — a CMS contractor, not your plan — reviews it. File within 60 days of receipt. Same decision clock as Level 1.

Level 3 — Hearing. An administrative law judge or attorney adjudicator. File within 60 days. Decision in 90 days, or 10 days if expedited. Requires the amount in controversy to be met.

Level 4 — Medicare Appeals Council. File within 60 days. Decision in 90 days, or 10 days expedited. No dollar threshold.

Level 5 — Federal district court. File within 60 days of the Council's decision, if the judicial-review threshold is met.

One more, specific to formulary exceptions

If you are requesting an exception — asking the plan to cover a drug it does not list, or to charge a lower tier — the bottleneck is almost always your prescriber's supporting statement.

At the Independent Review Entity level, if that statement has not arrived, the review can be extended by up to 14 additional days while they wait for it.

So chase it. Confirm with the prescriber's office that it was sent, to which fax or portal, and on what date. Ask for a copy for your own records. It is the single highest-value thing you can do while an exception request is pending, and it is entirely within your control.

Why this is worth the effort

A denial is frequently a documentation problem rather than a verdict — a missing baseline weight, an undocumented prior therapy, a diagnosis code that never made it onto the form. Those are fixable, and the appeal machinery exists precisely to fix them.

What is not fixable by appeal is a benefit exclusion. If your plan simply does not cover a category of drug, that is what your plan purchased, not a clinical judgment about you — and no amount of medical evidence changes it. Recognizing which one you are facing, early, is the difference between a productive month and a wasted one.

If you want the GLP-1-specific version of this — which denial reasons map to which fix, what documentation to gather before you file, and how to structure a peer-to-peer review — I maintain a detailed walkthrough here: how to appeal a GLP-1 insurance denial. The formulary exception guide covers the three different exception types, since asking for the wrong one costs you a review cycle.

Sources

• 42 CFR 423.582 — Right to a redetermination: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-423/subpart-M/section-423.582
• 42 CFR 423.590 — Timeframes and responsibility for making redeterminations: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-423/subpart-M/section-423.590
• 42 CFR 423.600 — Reconsideration by the independent review entity: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-423/subpart-M/section-423.600
• 42 CFR Part 423, Subpart U — Levels 3 through 5: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-423/subpart-U
• Medicare Program; Medicare Appeals: Adjustment to the Amount in Controversy Threshold Amounts for Calendar Year 2026 (CMS–4209–N), 90 FR 55869, December 4, 2025: https://www.govinfo.gov/content/pkg/FR-2025-12-04/pdf/2025-21879.pdf
• CMS — Part D appeals overview: https://www.cms.gov/medicare/appeals-grievances/prescription-drug/appeals-overview

Regulations checked July 2026. Rules and dollar thresholds change — verify against the current text before relying on any deadline.

This is general information about how the appeals process works, not legal, insurance, or medical advice. Your plan documents govern your specific situation.